Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Free Cash Flow (2020 - 2025)

Tarsus Pharmaceuticals has reported Free Cash Flow over the past 6 years, most recently at $21.3 million for Q4 2025.

  • Quarterly results put Free Cash Flow at $21.3 million for Q4 2025, up 195.71% from a year ago — trailing twelve months through Dec 2025 was -$14.0 million (up 83.47% YoY), and the annual figure for FY2025 was -$14.0 million, up 83.47%.
  • Free Cash Flow for Q4 2025 was $21.3 million at Tarsus Pharmaceuticals, up from $15.1 million in the prior quarter.
  • Over the last five years, Free Cash Flow for TARS hit a ceiling of $21.3 million in Q4 2025 and a floor of -$39.3 million in Q4 2023.
  • Median Free Cash Flow over the past 5 years was -$15.4 million (2022), compared with a mean of -$13.2 million.
  • Peak annual rise in Free Cash Flow hit 798.22% in 2021, while the deepest fall reached 487.35% in 2021.
  • Tarsus Pharmaceuticals' Free Cash Flow stood at -$12.4 million in 2021, then rose by 12.46% to -$10.9 million in 2022, then crashed by 262.5% to -$39.3 million in 2023, then skyrocketed by 43.42% to -$22.3 million in 2024, then skyrocketed by 195.71% to $21.3 million in 2025.
  • The last three reported values for Free Cash Flow were $21.3 million (Q4 2025), $15.1 million (Q3 2025), and -$29.7 million (Q2 2025) per Business Quant data.